Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Isao Tsumiyama"'
Publikováno v:
Modern Rheumatology. 33:381-391
Objectives To assess the real-world safety and effectiveness of canakinumab in patients in Japan with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) or mevalonate kinase deficiency/hyperimmunoglobulinaemia D with periodic fever
Autor:
Krishnan Ramanathan, Jin Nakahara, Takahiko Saida, Martin Merschhemke, Wendy Su, Takayoshi Kurosawa, Dieter A. Häring, Roman Willi, Ratnakar Pingili, Bernd C. Kieseier, Denis V Sazonov, Martin Zalesak, Jun-ichi Kira, Isao Tsumiyama
Publikováno v:
Multiple Sclerosis Journal. 28:1229-1238
Background: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, has been developed as a treatment for relapsing multiple sclerosis (RMS) which can be self-administered at home. Objective: To investigate the efficacy and safety of ofatumu
Publikováno v:
Modern Rheumatology; Mar2023, Vol. 33 Issue 2, p381-391, 11p
Publikováno v:
Diabetes, Obesity and Metabolism. 22:1102-1110
Aims LIK066 (licogliflozin) is a dual sodium glucose co-transporter 1/2 inhibitor with potential benefits in weight loss. This study evaluated the efficacy, tolerability and safety of licogliflozin in Japanese adults with obesity. Materials and metho
Autor:
Hiroki Murayama, Naotsugu Oyama, Yohei Shinfuku, Tomoko Hayashi, Isao Tsumiyama, Tomoko Taniguchi
Publikováno v:
Expert opinion on pharmacotherapy. 21(1)
Background: Vildagliptin is a dipeptidyl peptidase-4 inhibitor that reduces glycemia in patients with type 2 diabetes mellitus (T2DM). When approved in 2013, data on vildagliptin combined with >750...
Autor:
Hiroki Murayama, Mitsutoshi Toda, Isao Tsumiyama, Naotsugu Oyama, Tomoko Taniguchi, Yohei Shinfuku, Yoshio Tanaka
Background: Vildagliptin is indicated for type 2 diabetes mellitus (T2DM); however, the onset and exacerbation of diabetic complications in Japanese T2DM patients treated with vildagliptin is unknown. Research design and methods: This 2-year post-mar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d18276745a2620703bdc4b16cf4eda1
Publikováno v:
Diabetes Therapy
Introduction To assess the efficacy and safety of vildagliptin as add-on therapy in Japanese patients with type 2 diabetes mellitus (T2DM), inadequately controlled on stable long-acting, intermediate-acting, or pre-mixed insulin, with or without conc
Autor:
Takahiko Saida, Yasuto Itoyama, Seiji Kikuchi, Qi Hao, Takayoshi Kurosawa, Kengo Ueda, Lixin Zhang Auberson, Isao Tsumiyama, Kazuo Nagato, Jun-ichi Kira, Saida, Takahiko, Itoyama, Yasuto, Kikuchi, Seiji, Hao, Qi, Kurosawa, Takayoshi, Ueda, Kengo, Auberson, Lixin Zhang, Tsumiyama, Isao, Nagato, Kazuo, Kira, Jun-Ichi
Publikováno v:
BMC Neurology; 1/28/2017, Vol. 17, p1-10, 10p, 1 Diagram, 2 Charts, 3 Graphs
Autor:
Jun-ichi Kira, Yasuto Itoyama, Seiji Kikuchi, Qi Hao, Takayoshi Kurosawa, Kazuo Nagato, Isao Tsumiyama, von Rosenstiel, Philipp, Lixin Zhang-Auberson, Takahiko Saida
Publikováno v:
BMC Neurology; 2014, Vol. 14 Issue 1, p1-22, 22p, 1 Diagram, 4 Charts, 2 Graphs
Autor:
Kazuo Nagato, Yasuto Itoyama, Philipp von Rosenstiel, Takayoshi Kurosawa, Takahiko Saida, Seiji Kikuchi, Lixin Zhang-Auberson, Jun Ichi Kira, Isao Tsumiyama, Qi Hao
Publikováno v:
BMC Neurology
Background A 6-month phase 2 study of fingolimod demonstrated efficacy and safety in Japanese patients with relapsing-remitting multiple sclerosis (MS). Here we report a 6-month observational extension that evaluated efficacy and safety in patients w